Global HIV Drugs Market Report 2024

HIV Drugs Global Market Report 2024 – By Type (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types), By Administration (Oral, Parenteral), By Application (Hospital Pharmacies, Retail Pharmacies, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 175 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
HIV Drugs Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

HIV Drugs Market Definition And Segments

HIV drug refers to an antiretroviral drug that is frequently used to treat HIV. HIV medications prevent the spread of the human immunodeficiency virus (HIV) or other retroviruses in the body. HIV can cause AIDS if it is not treated (acquired immunodeficiency syndrome). Currently, there is no cure that works well.

The main types of HIV drugs are nucleoside reverse transcriptase inhibitors (NRTs), non-nucleoside reverse transcriptase inhibitors (NNRT’s), protease inhibitors, integrate inhibitors, fusion inhibitors, chemokine receptor inhibitors, and others. Nucleoside reverse transcriptase inhibitors (NRTIs) are structural nucleoside analogs of DNA nucleotides that inhibit HIV-1 RT and viral replication by preventing reverse transcription of the HIV genome. The drugs are administered through oral and parenteral methods that are used by hospital pharmacies, retail pharmacies, online pharmacies, and others.

The HIV drugs market covered in this report is segmented –

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types

2) By Administration: Oral, Parenteral

3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

The HIV drugs market size has grown steadily in recent years. It will grow from $33.82 billion in 2023 to $35.33 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in HIV research and development spending, increased incidence of HIV infection, rise in awareness and economic growth in emerging markets.

The HIV drugs market size is expected to see steady growth in the next few years. It will grow to $41.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in HIV research and development spending, increased incidence of HIV infection, rise in awareness and economic growth in emerging markets. Major trends in the forecast period include investing in 3D bioprinting technology, new product innovations, developing multi-class combination products for HIV treatment and investing in strategic collaborations and agreements.

Repurposing HIV Drugs For COVID-19 Treatment

The novel COVID-19 outbreak has augmented the growth of the global HIV drug market. HIV drugs are repurposed to treat COVID-19 infections. Currently, several countries are evaluating and using antiretroviral drugs (For instance, lopinavir boosted with ritonavir (LPV/r)), for treating COVID-19 infection.

Elevated Awareness Initiatives Driving HIV Drug Market Growth

Increasing awareness among people regarding the diagnosis and treatment of HIV disease acts as an important driver for the growth of the HIV drug market. HIV/AIDS is one of the most chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease. For instance, in May 2023, according to a report published by the Minnesota Department of Health, a US-based state health agency, there was an 8% rise in the reported instances of newly diagnosed HIV infections, with a total of 298 cases recorded in 2021. The federal government agencies and various associations across the globe have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care.

Government Investment Catalyzing Growth in the HIV Drug Market

The increased government spending is expected to boost the growth of the HIV drugs market going forward. Government spending, also known as public spending or government expenditure, refers to the total amount of funds that a government allocates and disburses to finance its various functions, programs, and services. Increased government funding supports various aspects of the HIV drug market, from research and development to improving access, and awareness, and reducing the societal and economic burden of the disease. These investments have a positive impact on the market's growth and overall effectiveness in addressing the HIV or AIDS pandemic. For instance, in March 2023, according to the Budget of the U.S. Government report, published by the US government, in Joe Biden's Fiscal Year (FY) 2024 budget proposal, there was an allocation of $850 million in funding for the CDC, HRSA, IHS, and NIH to sustain and expand the implementation of the Ending the HIV Epidemic in the U.S. initiative. This marks a substantial increase of $277 million (48%) compared to the funding level enacted in FY23. Therefore, the increased government spending is driving the growth of the HIV drug market.

Major companies operating in the HIV drugs market report are Gilead Sciences Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Mylan N.V., Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China's National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutic Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, Alfa Rio Química Ltda., Globe Quimica S/A, Nortec Química S.A., AstraZeneca, Zion Medical, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

Side Effects Of Antiretroviral Therapy In HIV Or Aids Treatment

Side Effects of HIV Drugs have always been a major challenge in antiretroviral therapy. Antiretroviral drugs are used to treat HIV and AIDS as these drugs help lower viral load, control the growth of the virus, boost the ability to fight infections, prevent HIV transmission to others and help stop or slow down symptoms. These drugs come with both short-term side effects (diarrhea, difficulty in sleeping, dizziness, fatigue, headache, muscle pain) and long-term side effects (depression, diabetes, heart disease, insomnia). There are several side effects associated with the therapy, thus impacting the growth of the market.

Advancements In Multi-Class Combination Products

The antiretroviral drugs market is increasingly implementing multi-class combination products for the treatment of antiretroviral therapy. Combination drugs combine multiple medications into one drug form. Examples of multiclass combination drugs or single-tablet regimens (STRs) include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo). Based on drug class, drugs are segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Others. Multi-class Combination Products are the rising burden of HIV and new drug approval. According to WHO, In 2021, 1.5 million [1.1-2.0 million] people contracted HIV, and 650 000 [510 000-860 000] people died from HIV-related causes. Many companies are focusing on developing breakthrough products for the treatment through antiretroviral drugs to maintain their competitive advantage and penetrate new regional markets.

Innovative Developments In The HIV Drugs Market

Major companies operating in the HIV drugs market are developing new products, such as drugs for multi-drug resistant HIV to meet larger customer bases, more sales, and increase revenue. Drugs for multi-drug resistant HIV (MDR-HIV) refer to antiretroviral medications specifically designed to treat HIV infections in individuals who have developed resistance to multiple classes of antiretroviral drugs. For instance, in December 2022, Gilead Sciences Inc., a US-based pharmaceutical company, announced (U.S. Food and Drug Administration) FDA approval for Sunlenca (lenacapavir). This medication features a multi-stage mode of action that sets it apart from other antiviral agent classes that have been approved recently. It also has no known in vitro cross-resistance to other existing medication classes. Adults with HIV who are not sufficiently controlled by their existing medication regimen have a new, twice-yearly therapy alternative available to them with Sunlenca. Lenacapavir is being developed as the basis for Gilead's upcoming HIV treatments with the aim of providing a number of long-acting choices that help suit individual needs and preferences, which may help maximize outcomes and lessen care burden.

North America was the largest region in the HIV drugs market share in 2023. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the HIV drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The HIV drug market consists of sales of Tivicay, Triumeq, Truvada, and Vemlidy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The HIV drugs market research report is one of a series of new reports from The Business Research Company that provides HIV drugs market statistics, including HIV drugs industry global market size, regional shares, competitors with an HIV drugs market share, detailed HIV drugs market segments, market trends and opportunities, and any further data you may need to thrive in the HIV drugs industry. This HIV drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

HIV Drugs Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $35.33 billion
Revenue Forecast In 2033 $41.2 billion
Growth Rate CAGR of 3.9% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types
2) By Administration: Oral, Parenteral
3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Gilead Sciences Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co. Inc.; Boehringer Ingelheim International GmbH; Cipla; Aurobindo Pharma; AbbVie; Mylan N.V.; Emcure Pharmaceuticals; Micro Labs Limited; Northeast Pharmaceutical Group Co. Ltd; Dr. Reddy's Laboratories Ltd.; Sun Pharmaceutical Industries Ltd; Strides Arcolab Limited; Hetero Labs Limited; Shanghai Desano Bio-pharmaceutical Co.; Anhui Biochem Biopharmaceutical Co. Ltd.; China's National Health Commission (NHC); Shanghai Xinxing Medicine Co. Ltd.; China Meheco Xinxing Pharma Co. Ltd.; CytoDyn Inc.; Janssen Pharmaceutical; Bavarian Nordic; Roche Laboratories; Pharmstandard; Pharmasyntez; R-Pharm; Alium; ChemRar Group; Gritstone Oncology; Enzolytics Inc.; BioClonetics Immunotherapeutics Inc.; Dewpoint Therapeutics; Lyndra Therapeutics; Mylan N.V.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Teva Canada; ViiV Healthcare Canada; Alfa Rio Química Ltda.; Globe Quimica S/A; Nortec Química S.A.; AstraZeneca; Zion Medical; GSK; Abbott Laboratories; Aspen Pharmacare Limited; Pharmacare Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. HIV Drugs Market Characteristics

    3. HIV Drugs Market Trends And Strategies

    4. HIV Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global HIV Drugs Market Size and Growth

    5.1. Global HIV Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global HIV Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global HIV Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. HIV Drugs Market Segmentation

    6.1. Global HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

    Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

    Protease Inhibitors

    Integrate Inhibitors

    Fusion Inhibitors

    Chemokine Receptor Inhibitors

    Other Types

    6.2. Global HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Parenteral

    6.3. Global HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    Other Applications

    7. HIV Drugs Market Regional And Country Analysis

    7.1. Global HIV Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global HIV Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific HIV Drugs Market

    8.1. Asia-Pacific HIV Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China HIV Drugs Market

    9.1. China HIV Drugs Market Overview

    9.2. China HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India HIV Drugs Market

    10.1. India HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan HIV Drugs Market

    11.1. Japan HIV Drugs Market Overview

    11.2. Japan HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia HIV Drugs Market

    12.1. Australia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia HIV Drugs Market

    13.1. Indonesia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea HIV Drugs Market

    14.1. South Korea HIV Drugs Market Overview

    14.2. South Korea HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe HIV Drugs Market

    15.1. Western Europe HIV Drugs Market Overview

    15.2. Western Europe HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK HIV Drugs Market

    16.1. UK HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany HIV Drugs Market

    17.1. Germany HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France HIV Drugs Market

    18.1. France HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy HIV Drugs Market

    19.1. Italy HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain HIV Drugs Market

    20.1. Spain HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe HIV Drugs Market

    21.1. Eastern Europe HIV Drugs Market Overview

    21.2. Eastern Europe HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia HIV Drugs Market

    22.1. Russia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America HIV Drugs Market

    23.1. North America HIV Drugs Market Overview

    23.2. North America HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA HIV Drugs Market

    24.1. USA HIV Drugs Market Overview

    24.2. USA HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada HIV Drugs Market

    25.1. Canada HIV Drugs Market Overview

    25.2. Canada HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America HIV Drugs Market

    26.1. South America HIV Drugs Market Overview

    26.2. South America HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil HIV Drugs Market

    27.1. Brazil HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East HIV Drugs Market

    28.1. Middle East HIV Drugs Market Overview

    28.2. Middle East HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa HIV Drugs Market

    29.1. Africa HIV Drugs Market Overview

    29.2. Africa HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. HIV Drugs Market Competitive Landscape And Company Profiles

    30.1. HIV Drugs Market Competitive Landscape

    30.2. HIV Drugs Market Company Profiles

    30.2.1. Gilead Sciences Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. GlaxoSmithKline plc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Johnson & Johnson

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Merck & Co. Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Boehringer Ingelheim International GmbH

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. HIV Drugs Market Other Major And Innovative Companies

    31.1. Cipla

    31.2. Aurobindo Pharma

    31.3. AbbVie

    31.4. Mylan N.V.

    31.5. Emcure Pharmaceuticals

    31.6. Micro Labs Limited

    31.7. Northeast Pharmaceutical Group Co. Ltd

    31.8. Dr. Reddy's Laboratories Ltd.

    31.9. Sun Pharmaceutical Industries Ltd

    31.10. Strides Arcolab Limited

    31.11. Hetero Labs Limited

    31.12. Shanghai Desano Bio-pharmaceutical Co.

    31.13. Anhui Biochem Biopharmaceutical Co. Ltd.

    31.14. China's National Health Commission (NHC)

    31.15. Shanghai Xinxing Medicine Co. Ltd

    32. Global HIV Drugs Market Competitive Benchmarking

    33. Global HIV Drugs Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The HIV Drugs Market

    35. HIV Drugs Market Future Outlook and Potential Analysis

    35.1 HIV Drugs Market In 2028 - Countries Offering Most New Opportunities

    35.2 HIV Drugs Market In 2028 - Segments Offering Most New Opportunities

    35.3 HIV Drugs Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global HIV Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global HIV Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Gilead Sciences Inc. Financial Performance
  • Table 75: GlaxoSmithKline plc. Financial Performance
  • Table 76: Johnson & Johnson Financial Performance
  • Table 77: Merck & Co. Inc. Financial Performance
  • Table 78: Boehringer Ingelheim International GmbH Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global HIV Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global HIV Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Gilead Sciences Inc. Financial Performance
  • Figure 75: GlaxoSmithKline plc. Financial Performance
  • Figure 76: Johnson & Johnson Financial Performance
  • Figure 77: Merck & Co. Inc. Financial Performance
  • Figure 78: Boehringer Ingelheim International GmbH Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the HIV drugs market?

HIV drug refers to an antiretroviral drug that is frequently used to treat HIV. HIV medications prevent the spread of the human immunodeficiency virus (HIV) or other retroviruses in the body. HIV can cause AIDS if it is not treated (acquired immunodeficiency syndrome). Currently, there is no cure that works well. For further insights on the HIV drugs market, request a sample here

How will the HIV drugs market drivers and restraints affect the HIV drugs market dynamics? What forces will shape the HIV drugs industry going forward?

The HIV drugs market growth is aided by increasing awareness among people regarding the diagnosis and treatment of HIV disease. However, some HIV drugs market restraints include side effects of HIV drugs. For further insights on the HIV drugs market, request a sample here

What is the forecast market size or the forecast market value of the HIV drugs market?

The HIV drugs market is expected to reach $42.65 billion in 2027 at a rate of 5.1%. For further insights on the HIV drugs market, request a sample here

How is the HIV drugs market segmented?

The global HIV drugs market is segmented as
1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Other Types
2) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Applications
3) By Administration: Oral, Parenteral
For further insights on the HIV drugs market,
request a sample here

Which region has the largest share of the HIV drugs market? What are the largest region's market size and growth rate?

North America was the largest region in the HIV drugs market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the HIV drugs market?

Key competitors in the HIV drugs market are, ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson&Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H. Boehringer Sohn AG & Ko. KG), AbbVie, Inc., GlaxoSmithKline plc, Mylan Pharmaceuticals, Pfizer, TEVA PHARMACEUTICAL INDUSTRIES LTD, Hetero Drugs, Daiichi Sankyo, Emcure, AstraZeneca, CIPLA, Alexion Pharmaceuticals, Shionogi, Theratechnologies, Abbott Laboratories Inc. For further insights on the HIV drugs market, request a sample here.

What are the key trends in the HIV drugs market?

Major trends influencing the HIV drugs market include increasingly implementing multi-class combination products for the treatment of antiretroviral therapy. Combination drugs combine multiple medications into one drug form. For further insights on the HIV drugs market, request a sample here.

What are the major opportunities in the HIV drugs market? What are the strategies for the HIV drugs market?

For detailed insights on the major opportunities and strategies in the HIV drugs market, request a sample here.

How does the HIV drugs market relate to the overall economy and other similar markets?

For detailed insights on HIV drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the HIV drugs industry?

For detailed insights on the mergers and acquisitions in the HIV drugs industry, request a sample here.

What are the key dynamics influencing the HIV drugs market growth? SWOT analysis of the HIV drugs market.

For detailed insights on the key dynamics influencing the HIV drugs market growth and SWOT analysis of the HIV drugs industry, request a sample here.